Bicycle Therapeutics (FRA:50BA) Valuation Rank


FRA:50BA Bicycle Therapeutics PLC FRA:50BA
56 GF Score
Price €3.56
GF Value €12.81
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bicycle Therapeutics Valuation Rank Related Terms

FRA:50BA
56GF Score
Bicycle Therapeutics PLC FRA:50BA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.56 is trading 72.2% below its estimated GF Value™ of €12.81. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • Valuation Rank:
  • GF Value™: €12.81 vs. price of €3.56 (72.2% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score

Get the complete analysis for FRA:50BA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.56
Price
€12.81
GF Value